| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 4.05% | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -4744.25% | — | — | — | — | — | -445.60% | -960.12% | -941.36% | -1737.10% | -892.13% |
| EBITDA Margin | -4735.97% | — | — | — | — | — | -404.33% | -861.20% | -870.73% | -1656.75% | -857.18% |
| Net Margin | -4416.22% | — | — | — | — | — | -423.81% | -974.62% | -1019.26% | -1789.83% | -908.05% |
| Current Ratio | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 | 0.41 |
| Quick Ratio | 0.31 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 | 0.41 |
| Debt / Equity | — | — | — | — | — | — | -0.07 | -0.01 | -0.01 | -0.54 | -0.07 |
| ROE | 193.94% | 103.13% | 408.53% | -756.04% | -1153.86% | -1246.85% | 214.04% | 117.80% | 115.45% | 1025.53% | 86.37% |
| ROA | -335.90% | -261.48% | -182.61% | -231.54% | -233.06% | -178.59% | -201.48% | -135.04% | -187.37% | -224.96% | -135.38% |
| Asset Turnover | 0.08 | — | — | — | — | — | 0.48 | 0.14 | 0.18 | 0.13 | 0.15 |
| Book Value / Share | -0.93 | -3.94 | -0.06 | 0.04 | 0.03 | 0.04 | -0.89 | -0.65 | -1.40 | -0.30 | -5.63 |
Outlook Therapeutics Inc. is a late clinical-stage biopharmaceutical company specializing in ophthalmology. The company is focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed for the treatment of retinal diseases, particularly neovascular or “wet” age-related macular degeneration (wet AMD). Its lead product candidate seeks to provide a standardized, rigorously tested alternative to repackaged intravenous bevacizumab commonly used off-label in retinal care today. By concentrating on retina specialists and eye-care providers, Outlook Therapeutics aims to address important needs in dosing consistency, sterility, and regulatory oversight for anti-VEGF therapies used in vision-threatening conditions. Headquartered in Iselin, New Jersey, and founded in the United States, the company operates within the broader biotechnology and pharmaceutical markets, with a clear emphasis on improving treatment options for patients with serious retinal disorders.